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Abstract (Word Count: 166) 
Aims:  Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients 
with symptomatic heart failure (HF) and QRS prolongation but there is uncertainty about which 
patient characteristics predict short-term clinical response. 
Methods and Results: In an individual patient meta-analysis of three double-blind, randomized 
trials, Clinical Composite Score (CCS) at 6 months was compared in patients assigned to CRT 
programmed on compared to off. Treatment-covariate interactions were assessed to measure 
likelihood of improved CCS at 6 months. 
MIRACLE, MIRACLE ICD, and REVERSE trials contributed data for this analysis (n=1591). 
Multivariable modelling identified QRS duration and left ventricular ejection fraction (LVEF) as 
predictors of CRT clinical response (p<0.05). The odds ratio for a better CCS score at 6 months 
increased by 3.7% for every 1% decrease in LVEF for patients assigned to CRT-on compared to 
CRT-off, and was greatest when QRS duration was between 160 ms and 180 ms.  
Conclusions: In symptomatic chronic heart failure patients (NYHAII-IV), longer QRS duration 
and lower LVEF independently predict early clinical response to CRT.   
Key Words: Cardiac resynchronization therapy, heart failure, symptoms  
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ABBREVIATIONS 
CCS: Clinical composite score 
CRT:  Cardiac resynchronization therapy 
HF: Heart failure 
HFH: Heart failure hospitalization 
ICD: Implantable cardioverter defibrillator 
IPD: Individual Patient Data 
LBBB: Left bundle branch block 
LOCF: Last observation carried forward 
LVEF: Left ventricular ejection fraction 
NYHA: New York Heart Association 
  
  
Page 4 of 31 
 
INTRODUCTION 
Cardiac resynchronization therapy (CRT) is an established therapy for patients with heart 
failure (HF) with a reduced left ventricular ejection fraction (LVEF) and electrical dyssynchrony 
(1-3). Prospective randomized trials of CRT have consistently demonstrated reductions in heart 
failure related hospitalization (HFH) and mortality rate among patients with a broad spectrum of 
symptomatic HF (4-7). CRT can also improve symptoms or, in those with few or no symptoms, 
prevent deterioration. Although CRT makes a valuable contribution to HF management, it is 
relatively expensive and associated with complications. Additionally, not all HF patients 
improve with CRT, which highlights the need for better ways to predict who will benefit from 
this therapy within the first months of treatment when recommending CRT to the patient. 
We previously identified QRS duration as the only significant predictor of morbidity and 
mortality benefit after adjusting for covariates (5). Although morbidity and mortality are “hard” 
endpoints in clinical trials, they identify only patients who worsen. For patients with a disease 
that is likely to progress, such as HF, prevention of deterioration may be just as important (8). 
The present analyses pooled patient-level data from three randomized trials to assess baseline 
predictors for short-term clinical response to CRT, defined either as an improvement or 
maintenance of HF status depending on symptom severity at baseline. 
 
METHODS 
Individual patient data (IPD) from three randomized controlled trials sponsored by one 
manufacturer (Medtronic plc, Minneapolis, USA) comparing CRT programmed on or off were 
pooled for this analysis. The studies were selected because they were double-blind and had the 
Clinical Composite Score (CCS) as a primary (REVERSE) or secondary (MIRACLE and 
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MIRACLE ICD) outcome. All included studies complied with the Declaration of Helsinki, the 
locally appointed ethics committees approved the research protocol for each study, and all 
patients provided written informed consent. Data were pooled for 1591 patients comparing either 
CRT with back-up pacing (MIRACLE (9), REVERSE (10, 11)) or CRT-D with ICD (REVERSE 
(10, 11), MIRACLE-ICD (12, 13)). In the control arm backup right ventricular pacing (VVI) was 
programmed to allow for intrinsic rhythm as much as possible and was VVI 30 in MIRACLE (9) 
and VVI 35 in MIRACLEICD (12,13) and VVI 35 REVERSE (10,11). In all trials, patients and 
endpoint assessment study personnel were blinded to treatment. In order to create a more 
homogeneous population, patients in New York Heart Association (NYHA) class I (107 patients 
from REVERSE) were excluded. The remaining patients were in NYHA III/IV 
(MIRACLE/MIRACLE ICD) or NYHA II (MIRACLE ICD/REVERSE). All patients were on 
guideline-recommended pharmacological therapy for HF before being randomized.  
The following pre-specified baseline variables were included in the analyses: age, sex, 
NYHA class, etiology, QRS morphology, QRS duration, left ventricular ejection fraction 
(LVEF), and systolic blood pressure. Core-laboratory values were used for ECG measurements 
in REVERSE and for echocardiographic assessment of LVEF in all studies.  
Short-term (6 months) response in Clinical composite Score (CCS) 
Our outcome for this analysis was the CCS at 6 months (14) developed and used to assess 
HF patients in many CRT trials (13-17). The CCS classifies patients as Worsened, Unchanged, 
or Improved based upon mortality, HF hospitalization, cross-over from assigned randomization, 
NYHA class, and the patient’s own global assessment of their HF state. The global assessment 
uses seven response options: markedly improved; moderately improved; mild improvement; no 
change; slightly worse; moderately worse; or markedly worse to define whether overall status 
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has changed and, if so, in which direction and magnitude compared to baseline. Markedly or 
moderately improved was considered as a positive response to treatment assignment, markedly 
or moderately worse as a negative response, and mildly worse or improved or unchanged was 
judged as no change with assigned treatment. Only in the REVERSE trial were both Improved 
and Unchanged regarded as a positive response to treatment since this study included patients in 
mild HF and thus hypothesized prevention of disease progression with CRT.  
Based on all components of the CCS, patients were classified as Worsened if a) they died 
or were hospitalized for worsening HF, b) crossed over to the alternate treatment, or permanently 
discontinued double-blind treatment due to worsening HF, or c) had a worsening in NYHA 
functional class or reported a moderate or marked worsening of HF symptoms. Patients were 
classified as Improved if they did not fulfill the criteria for Worsened and had an improvement in 
NYHA functional class, or had a moderate or marked improvement in global assessment, or 
both. Patients who were neither Worsened nor Improved were classified as Unchanged.  
The CCS thus leverages objective measures of death and HFH in combination with 
subjective measures of NYHA functional class and global assessment. Importantly, CCS 
accounts for discontinuation of therapy due to clinical deterioration. A hierarchical model was 
used to identify whether the subject’s status Improved, Worsened, or is Unchanged , placing 
priority on death, HFH, crossovers, then patient subjective measures. CCS was a last-
observation-carried-forward (LOCF) metric, and so was available at 6 months for all patients. 
Inclusion of patients for analysis of short-term response was dependent on whether all baseline 
characteristics pre-specified for this analysis were available.  
Statistics 
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 Statistical analyses were conducted using the intention-to-treat principle and included 
patients who failed to receive their assigned treatment (5). Continuously distributed data are 
shown as both mean and standard deviation and median, inter-quartile range, and full range. 
Categorical data are shown as percentages. A cumulative logits model was used to assess early 
response due to the tripartite nature of the CCS. This model included main effects of the 
covariates defined above as well as corresponding interaction effects with CRT therapy, and 
simultaneously evaluated how these covariates impacted the likelihood of an Improved score at 6 
months as well as the likelihood of an Improved/Unchanged score at 6 months. Quantitative 
variables (age, QRS duration, LVEF, systolic blood pressure) were treated as continuous 
variables in the models. Patients in NYHA class III were enrolled in all studies except 
REVERSE and served as the default for calculating odds ratios, the primary metric of 
comparison. The odds ratio reflected the odds of superior (e.g. Improved/Unchanged) CCS 
among patients with a characteristic or therapy (e.g. with CRT, with NYHA II) compared to 
those without it. Scores above 1 showed evidence of greater likelihood of superior CCS scores 
among patients having the characteristic/therapy of interest. Backwards elimination was applied 
for final model selection.  
Estimated Relative Risk (referred to hereafter as Relative Benefit) denoting the ratio of 
the estimated probability of a CCS score of Improved with CRT over the corresponding 
probability without CRT was plotted based on modeling results for subgroups defined by 
significant main effects, with a value over 1 indicative of CRT benefit. Plots were generated for 
subgroups thought to be most representative of the individual MIRACLE, MIRACLE-ICD, and 
REVERSE populations but also indicative of contemporary treatment patterns such as beta-
blocker usage which is higher to date than at the time when the studies were carried out.  
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RESULTS 
Of 1599 patients eligible for this analysis1591 had sufficient baseline data to be included 
(882 in the CRT group and 717 in the Control group), (Table 1). The two cohorts were similar 
with regard to concomitant ICD therapy, age, gender, LVEF, QRS duration, and blood pressure. 
In the CRT group, there were slightly more patients in NYHA II and more patients were on a 
beta blockers, due to the 2:1 randomization scheme employed in REVERSE which was contrary 
to the 1:1 assignment in MIRACLE and MIRACLE ICD. Only a few patients in REVERSE 
received a CRT-P device; therefore, amongst NYHA II patients, the comparison was 
predominantly CRT-D versus ICD only. Regarding HF medication, ACE inhibitors or 
Angiotensin receptor II blockers were given in 91, 93 and 97% in the MIRACLE, MIRACLE 
ICD and REVERSE patients respectively. Beta-blockers were given in 95% of REVERSE 
patients compared to 56 and 61% in the MIRACLE and MIRACLE ICD trials, respectively. 
LVEF was on the average 24.6% and QRS width 161 ms. 
The breakdown of Worsened, Unchanged, and Improved among CRT patients was 16%, 
24%, and 60%, respectively; among Control patients the corresponding breakdown was 26%, 
33%, 41% (Table 2). For many patients in both the CRT and Control arms, Improved scores 
were due to both NYHA and Global Assessment improvement (29% and 17%, respectively). 
Worsened CCS among CRT and Control patients was most commonly due to HFH (7% and 
12%, respectively). 
CRT (ON vs OFF), ICD therapy/indication (Yes/No), NYHA II symptoms, LBBB, 
LVEF, and beta blocker therapy at enrollment were found to each significantly affect a subject’s 
odds of a better CCS at 6 months when accounting for other predictors (Table 3). However, the 
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interaction effect for CRT was only significant with LVEF (p=0.0126) and with baseline QRS 
duration. The nature of the interaction effect of QRS duration with CRT was curvilinear 
(p=0.0005 and p=0.0026 for linear and quadratic interaction terms, respectively).    
CRT exerted a greater benefit in patients with lower ejection fractions and longer QRS 
durations and was greatest when QRS duration was between 160 ms and 180 ms (Figure 1). 
CRT benefit (odds ratio >1) was consistent for LVEF >19% only when QRS duration was >140 
ms (Figure 1). However, for LVEF <19% (n=347), the estimated odds ratio exceeded 1 
regardless of QRS duration, exceeding an estimated odds ratio of 4 for some QRS durations; in 
other words, the odds for being Improved at 6 months was 4 times higher with rather than 
without CRT in this subset of patients with severe HF disease state. There were 63 patients (4% 
of the cohort) with an LVEF < 19% and a QRS duration < 140 ms. 
For patients in NYHA III/IV with LBBB and on beta blockers with or without an ICD, 
the relative benefit of CRT was as high as 2.4 (Figure 2A, 3A). In addition, patients could also 
improve if CRT was not programmed on; the probability of this happening was similar 
regardless of QRS duration but was less likely in patients with a lower LVEF (Figure 2B, 3B). 
Among CRT patients the probability of benefit decreased at lower LVEF, but not as much as in 
patients who did not receive CRT pacing. For CRT patients, the probability for benefit increased 
with QRS duration and leveled off at approximately 170 ms (Figure 2C, 3C).   
For patients in NYHA II, almost all of whom had an ICD, the estimated relative benefit 
of an Improved CCS at 6 months with CRT was similar. Broadening the definition of success in 
this group to include Improved or Unchanged resulted in a smaller relative benefit (Figure 4A) 
than that for Improved alone, because of the high probability of patients being Unchanged even 
if CRT was programmed off (Figure 4B) and thus the smaller relative difference with that of the 
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CRT arm (Figure 4C). However, the estimated relative benefit was still between 1.1 and 1.4 
over much of the range of LVEF and QRS durations (Figure 4A), suggestive of a 10 - 40% 
increase in likelihood of a 6 month CCS of Improved/Unchanged with CRT.  
 
DISCUSSION 
This IPD meta-analysis of double-blind randomized trials confirms that CRT improves a 
composite of symptoms and outcome by six months and that patients with a lower LVEF and a 
longer QRS duration are more likely to benefit. After adjusting for confounding (interacting) 
variables, which is not possible with a conventional meta-analysis, only QRS duration and LVEF 
were significant predictors of clinical response to CRT. These findings build on our previous 
observations in a similar IPD meta-analysis that QRS duration was the only independent 
predictor of the effect of CRT on morbidity and mortality but focus on the short term response 
which is also important for the patient (5).  
Previous studies have indicated that LBBB is a univariate predictor of response to CRT 
but not always a significant predictor after adjusting for covariates (15-18). Several subgroup 
analyses from randomized clinical trials and single-center studies have suggested that patients 
without LBBB may derive less benefit from CRT (19-23). In MADIT-CRT, there was a trend for 
increased mortality from CRT in non-LBBB patients despite indications of reverse remodeling 
(18). However, patients with LBBB have longer QRS durations (mean= 163±19 ms) compared 
to those without LBBB (mean = 146±15 ms) and are less likely to have ischemic heart disease 
(18). After adjusting for covariates, QRS morphology may no longer be a statistically significant 
predictor of the response to CRT but might nonetheless be an important clinical substrate. 
Clearly, this is a controversial area that requires more evidence and thought. 
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Many analyses exploring predictors of the response to CRT lack a control group. These 
analyses can predict the outcome with a therapy but not the response to it (24). In order to know 
what the response to a therapy is, the response of similar patients without the intervention must 
be known, preferably from a double-blind randomized trial. In our analysis the probability of an 
improvement without CRT was consistent across QRS duration but decreased in patients with a 
lower LVEF. Device therapy including CRT has a placebo-effect (11, 12, 25) particularly over a 
short term time period (26). Patients will also improve in response to changes in lifestyle and 
pharmacological therapy. This analysis shows the importance of having a control group to ensure 
that the effects of the intervention can be distinguished from the natural history of the disease. In 
this analysis heart failure hospitalizations were clearly the most common reason for patients 
worsening in both study groups but were especially pronounced in the CRT off group.  
In our study several baseline variables (ICD therapy, NYHA II symptoms, 
presence/history of  LBBB, LVEF, and beta blocker usage at baseline) were found to 
significantly affect a patient’s odds of improved clinical response at 6 months. However, when 
examining the interaction effect for CRT, only QRS duration and LVEF were significant. This 
suggests that some variables such as these influence the progression of HF whether or not the 
patient receives CRT. Our finding contrasts with previous studies which suggest that patient 
characteristics such as older age, male sex, RBBB, and ischemic etiology are linked to less 
benefit from CRT (21, 24, 27, 28). However, these studies either lack a control group or 
statistical power. We used individual patient data rather than aggregated data, and studied the 
interaction between QRS duration and morphology as well as interaction with CRT therapy. Our 
results thus, represent a much more robust analysis than other meta-analyses (19-23).   
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Our results may contribute information to new guidelines. Currently, CRT is most 
strongly recommended for symptomatic HF patients with an LVEF ≤30 or 35% with a QRS 
duration ≥150 ms and LBBB, with a weaker recommendation for patients without LBBB and in 
less prolonged QRS (120 ms or 130 ms) (29-31). The most recent guidelines from the European 
Society of Cardiology (32) stress the importance of not implanting CRT in patients with QRS < 
130 ms based on the ECHO CRT study (33) since CRT was linked to excess mortality in this 
study. Our new findings, focusing on the short-term clinical response to CRT suggest clinical 
benefit from CRT in patients with QRS ≥140 irrespective of bundle branch morphology and that 
patients with a lower LVEF are more likely to benefit from CRT even at a modest QRS 
prolongation of QRS duration < 140 ms. In our meta-analysis such patients were few and 
represent a small subgroup making it difficult to draw solid conclusions. In contrast, in the 
ECHO CRT only patients with QRS < 130 ms were included.   
For the patient it is relevant to get the treating physician’s view on what to expect from 
CRT when making a decision on whether to be implanted or not. Symptomatic improvement 
over the first months of treatment may be important for the patient irrespective of any long term 
benefits on morbidity and mortality. We clearly show strong evidence for symptomatic 
improvements after 6 months of CRT therapy by the endpoint in this meta-analysis – the CCS. 
This endpoint has several advantages. It includes components of symptomatic improvement such 
as NYHA class estimated by study professionals and global assessment questions on symptoms 
answered by the patients. A further strength of CCS is that, unlike other endpoints, every patient 
contributes to the analysis through the tested duration. A component of the CCS is NYHA class, 
which itself has been used as an endpoint in CRT trials (9). Our results are strengthened by the 
fact that all studies included in this analysis assessed NYHA class in a blinded manner.  
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Our analysis also puts the response rate to CRT into perspective by relating it to 
important baselines covariates. Defining patient response across multiple subgroups is important 
for translating findings from a clinical trial to a “real-world” HF population. Careful patient 
selection is essential in obtaining the most benefit from existing CRT technologies. While 
different strategies to improve response are advancing, such as lead placement, imaging, and 
device programming, our analysis indicates that these approaches need to show that they are 
superior to selection by both QRS duration and LVEF. Although morbidity and mortality are 
important gold-standards for the assessment of many treatments for heart failure, they have 
weaknesses. They may not be the most important goals of therapy either for those who have very 
severe or very mild symptoms. For the former group, relief of symptoms may be more important. 
For the latter group, morbidity and mortality may already be low and the main medium-term goal 
may be delaying or preventing the progression of disease. Indeed in our study the proportion 
worsening was more common in the control group and was driven by heart failure 
hospitalizations whereas improvement was more common in the CRT group and was driven by 
patient´s global assessment or NYHA class. The CCS balances a clinical outcome that is 
meaningful to both patients and clinicians with a robust measurement that increases the 
feasibility of conducting trials of sufficient size and duration to identify important effects. 
 
Limitations 
An important limitation of this analysis was the restriction to those studies in which we 
had access to individual patient data. As in all clinical trials, care should be taken in interpreting 
data from subgroups and in extrapolating data gathered from patients selected for a clinical trial 
to the wider patient population that might be considered for CRT. However, these analyses 
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included a large patient population with heterogeneity in symptom severity and intervention 
(ICD vs. CRT). Results of our analysis indicated these background differences did not influence 
the response to CRT. Choice of baseline covariates to evaluate was predefined, and not based on 
minimum sample size requirements for subgroups; it is not known how or whether this affected 
analysis results.  
Conclusions 
In a meta-analysis of double-blind randomized controlled trials, longer QRS duration and 
lower LVEF predict a favorable response to CRT defined as improvement at 6 months in 
Clinical Composite Score; a measure driven mainly by symptom status.  
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Figure Legends 
 
Figure 1:  Estimated Odds Ratio of CRT programmed on versus off on 6 month CCS by 
QRS Duration and by LVEF.  Odds ratio increases as LVEF decreases, and for each LVEF 
value is greatest when QRS duration is between 160 and 180 ms. 
Figure 2:  Estimated Probability of an Improved CCS at 6 Months (ICD, Beta Blockers, 
LBBB, NYHA III/IV). Estimated Relative Benefit (2A) and probability of 6 Month CCS score 
of Improved for patients with CRT programmed off (2B) and CRT programmed on (2C) for 
patients in NYHA III/IV with an ICD, LBBB and on Beta Blockers. Relative benefit scores (2A) 
over 1 denote greater likelihood of Improved scores with CRT. Y-axis for 2B and 2C denote 
probability (0.25 = 25%) 
Figure 3:  Estimated Probability of an Improved CCS at 6 Months (Non-ICD, Beta 
Blockers, LBBB, NYHA III/IV). Estimated Relative Benefit (3A) and probability of 6 Month 
CCS score of Improved for CRT programmed off (3B) and CRT programmed on (3C) for 
patients in NYHA III/IV, without an ICD but with LBBB and on Beta Blockers.  Relative benefit 
scores over 1 denote greater likelihood of Improved scores with CRT. 
Figure 4:  Estimated Probability of an Improved/Unchanged CCS at 6 Months (ICD, Beta 
Blockers, LBBB, NYHA II). Estimated Relative Benefit (4A) and probability of 6 Month CCS 
score of Improved or Unchanged for CRT programmed off (4B) and CRT programmed on (4C) 
for patients in NYHA II with an ICD, LBBB and on Beta Blockers.  Relative benefit scores over 
1 denote greater likelihood of Improved/Unchanged scores with CRT.
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Table 1: Patient Characteristics 
Patient and Study Characteristics 
CRT  
(N=882) 
Control 
(N=717) 
Study   
   MIRACLE 266 (30.2%) 275 (38.4%) 
   MIRACLE-ICD 272 (30.8%) 283 (39.5%) 
   REVERSE 344 (39.0%) 159 (22.2%) 
Gender (N, %)   
   Male 666 (75.5%) 551 (76.8%) 
   Female 216 (24.5%) 166 (23.2%) 
Concomitant ICD therapy 556 (63.0%) 421 (58.7%) 
Age (years at baseline visit)   
   Mean  Standard Deviation 64.1 ± 11.1 64.4 ± 11.2 
   Median 65.5 66.0 
   25th Percentile – 75th Percentile  56.9 – 72.1 57.5 – 73.2 
   Minimum – Maximum 23.0 – 89.0 20.4 – 93.8 
Baseline Left Ventricular Ejection Fraction   
   Mean  Standard Deviation 24.7 ± 7.0 24.4 ± 7.0 
   Median 24.5 24.0 
   25th Percentile – 75th Percentile  20.0 – 29.1 19.8 – 29.5 
   Minimum – Maximum 8.9 – 51.6 6.0 – 45.0 
   N (%) of Patients with LVEF Avail. 881 (99.9%) 717 (100%) 
Baseline QRS Duration   
   Mean  Standard Deviation 160.6 ± 23.2 161.6 ± 22.4 
   Median 160.0 160.0 
   25th Percentile – 75th Percentile  144 – 176 145 – 176 
   Minimum – Maximum 93 – 250 80 – 240 
   N (%) of Patients with QRS Avail. 882 (100%) 717 (100%) 
Baseline Supine Systolic BP   
   Mean  Standard Deviation 118.8 ± 18.7 116.8 ± 18.1 
   Median 118 114 
   25th Percentile – 75th Percentile  106 – 130 105 – 128 
   Minimum – Maximum 74 – 205 78 – 183 
   N (%) of Patients with BP Avail. 880 (99.8%) 712 (99.3%) 
Baseline Supine Diastolic BP   
   Mean  Standard Deviation 69.6 ± 10.9 68.7 ± 10.7 
   Median 70 70 
   25th Percentile – 75th Percentile  60 – 78 60 – 76 
   Minimum – Maximum 35 – 112 42 – 110 
   N (%) of Patients with Measurement 880 (99.8%) 712 (99.3%) 
NYHA Classification   
   NYHA II 429 (48.6%) 260 (36.3%) 
   NYHA III 404 (45.8%) 410 (57.2%) 
   NYHA IV 49 (5.6%) 47 (6.6%) 
Morphology   
   Left Bundle Branch Block* 639 (72.4%) 509 (71.0%) 
   Right Bundle Branch Block† 82 (9.3%) 92 (12.8%) 
   Neither 166 (18.8%) 125 (17.4%) 
 Ischemic 493 (55.9%) 432 (60.3%) 
Beta Blocker Usage at Baseline 654 (74.2%) 465 (64.9%) 
*LBBB status not known for some patients  
†There were some patients with both a history of LBBB and RBBB; these are counted in both groups  
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Table 2: CCS Breakdown Among CRT and Control Subjects 
CCS Reason Control 
(N=717) 
CRT 
(N=882) 
Improved N(%) 297 (41.42) 525 (59.52) 
Global Assessment 72 (10.04) 131 (14.85) 
NYHA 102 (14.23) 137 (15.53) 
NYHA & Global Assessment 123 (17.15) 257 (29.14) 
Unchanged N(%) 236 (32.91) 215 (24.38) 
Worsened N(%) 184 (25.66) 142 (16.10) 
Death 37 (5.16) 36 (4.08) 
Exit 3 (0.42) 3 (0.34) 
Global Assessment 15 (2.09) 10 (1.13) 
HFH 83 (11.58) 60 (6.80) 
NYHA 33 (4.60) 24 (2.72) 
Crossover/Reprogram 13 (1.81) 9 (1.02) 
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Table 3:  Main Modelling Results for Short-Term Response 
 Short-term Response at 6 Months 
Odds Ratio P-value  
Main Effects   
   ICD Therapy 0.773 0.0253 
   CRT Therapy 0.546 0.0382 
   Age at Baseline NS NS 
   NYHA II 1.370 0.0090 
   NYHA IV NS NS 
   Left Bundle Branch Block 1.447 0.0013 
   Ischemic Heart Disease NS NS 
   Gender: Male NS NS 
   Beta Blocker Use at baseline 1.442 0.0010 
   Systolic BP at baseline NS NS 
   QRS Duration (linear) 0.990 NS 
   QRS Duration (quadratic) 1.0001 NS 
   LVEF (linear) 1.057 <0.0001 
   LVEF (quadratic) NS NS 
Interaction with Effect of  
CRT 
  
   ICD Therapy NS NS 
   Age at Baseline NS NS 
   NYHA II NS NS 
   NYHA IV NS NS 
   Left Bundle Branch Block NS NS 
   Ischemic Heart Disease NS NS 
   Gender: Male NS NS 
   QRS Duration (linear) 1.044 0.0005 
   QRS Duration (quadratic) 0.9996 0.0026 
   LVEF (linear) 0.964 0.0126 
   LVEF (quadratic) NS NS 
   Β-Blocker Use at baseline NS NS 
   Systolic BP at baseline NS NS 
Items in bold are statistically significant at p<0.05 
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